Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Oct 31 - Nov 5
The data on these drugs is already stark: Between 810% of Americans are currently using GLP-1 drugs (roughly the population of Texas) Projections suggest that by 2030 this will rise to 1415% Americans - with global demand also expected to surge Users of these GLP-1 drugs are cutting their grocery spending by up to 9%, with consumption of snacks, sweets, and sugary drinks plummeting Morgan Stanley predicts a 3-4% drop in these categories by 2035, with some estimates much higher This isn't a fad, it's a growing threat to brands built on indulgence and an enormous opportunity for those ready to adapt
By promoting weight loss, semaglutide may help reduce the risk and severity of these obesity-related conditions, leading to improved overall health outcomes
Regular follow-up appointments are essential for anyone taking tirzepatide for weight loss
Feb 2018;4(1):6-12
Jardiance and EMPA-REG OUTCOME are registered trademarks of Boehringer Ingelheim
US$ 22.64
US$ 27.78
US$ 20.18
US$ 26.86
US$ 23.70
US$ 24.29
US$ 27.42
US$ 24.06
US$ 26.04
US$ 25.61
US$ 24.80
US$ 28.33
US$ 20.93
US$ 23.87
US$ 21.29
US$ 24.37
